Company profile: Agenus
1.1 - Company Overview
Company description
- Provider of immunotherapies and vaccines for cancer and infectious diseases, advancing antibodies that activate antitumor immunity: botensilimab (CTLA-4; Phase 2 in melanoma, MSS colorectal and pancreatic cancers), balstilimab (PD-1; backbone for combinations), zalifrelimab (CTLA-4), AGEN2373 (CD137 agonist), AGEN1571 (ILT-2 antagonist), and an anti-ILT4 antagonist developed with pembrolizumab and chemotherapy.
Products and services
- Botensilimab: Fc-engineered CTLA-4 antibody that activates T cells, eliminates regulatory T cells, and establishes memory cells for durable immunity
- In phase 2 for melanoma, MSS colorectal, and pancreatic cancers
- Balstilimab: Checkpoint inhibitor-class PD-1 antagonist that reactivates exhausted T cells, demonstrates activity in PD-L1–positive and negative cervical cancer, and serves as a backbone for combination trials
- Zalifrelimab: Ligand-blocking CTLA-4 antagonist that prevents CTLA-4 binding partner interactions, driving T-cell activation and tumor killing, with demonstrated efficacy across indications including cervical cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Agenus
Vir Biotechnology
HQ: United States
Website
- Description: Provider of immunology-based products to treat and prevent infectious diseases and other serious conditions, including Phase 2 tobevibart + elebsiran for chronic hepatitis delta and elebsiran + PEG-IFN-α for chronic hepatitis B; Phase 1 VIR-1388 for HIV prevention; and preclinical candidates VIR-8190 (RSV & hMPV), VIR-2981 (influenza A/B), and VIR-1949 (pre-cancerous HPV lesions).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vir Biotechnology company profile →
Luminary Therapeutics
HQ: United States
Website
- Description: Provider of preclinical cell therapies for cancer and autoimmune diseases, including the Allogeneic Gamma 2.0+ platform for B-cell malignancies; Split Co-Stim Dual CAR targeting multiple solid tumor antigens, designed to enhance persistence and prevent T cell exhaustion; BAFF ligand-based CAR addressing BAFF, BCMA, and TACI to mitigate antigen escape; and a non-viral TcBuster transposon process for cost-efficient CAR-T manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Luminary Therapeutics company profile →
Sellas Life Sciences
HQ: Bermuda
Website
- Description: Provider of late-stage cancer immunotherapies, developing Galinpepimut-S (GPS), a WT1-targeting synthetic heteroclitic epitope immunotherapeutic for various cancers to prevent relapses and potentially improve survival, and SLS009, a highly selective small molecule CDK9 inhibitor for development and commercialization worldwide outside the Greater China Region.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sellas Life Sciences company profile →
Tmunity Therapeutics
HQ: United States
Website
- Description: Provider of engineered T cell therapies and platforms, developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms to unleash the immunological potential of T cells, treat a wide range of disease indications, and enable control over T cell activation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tmunity Therapeutics company profile →
Alzamend Neuro
HQ: United States
Website
- Description: Provider of biotech therapies for Alzheimer's disease that develops and commercializes drugs, treatments, and cures. Includes AL001, an ionic cocrystal delivering lithium via lithium/proline/salicylate for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD; and ALZN002, a cell-based therapeutic vaccine using a mutant-peptide sensitized cell to restore the patient's immune system's ability to combat Alzheimer's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alzamend Neuro company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Agenus
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Agenus
2.2 - Growth funds investing in similar companies to Agenus
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Agenus
4.2 - Public trading comparable groups for Agenus
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →